Cargando…

The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years

BACKGROUND: Data on Human Papilloma virus (HPV) vaccine immune response in sub-Saharan Africa is still sparse yet such knowledge is critical for optimal implementation and monitoring of HPV vaccines. Our primary objective was to evaluate levels of anti-HPV-16/18 antibodies and six other ‘high risk’...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakalembe, Miriam, Banura, Cecily, Namujju, Proscovia B, Mirembe, Florence M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158334/ https://www.ncbi.nlm.nih.gov/pubmed/25206925 http://dx.doi.org/10.1186/1750-9378-9-29

Ejemplares similares

Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67
por: Chen, Zigui, et al.
Publicado: (2011)

Universal routine HPV vaccination for young girls in Uganda: a review of opportunities and potential obstacles
por: Banura, Cecily, et al.
Publicado: (2012)

A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model
por: Yin, Fei, et al.
Publicado: (2017)

Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review
por: Banura, Cecily, et al.
Publicado: (2011)

Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand
por: Khunamornpong, Surapan, et al.
Publicado: (2016)

Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence
por: Namujju, Proscovia B, et al.
Publicado: (2011)

Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
por: Wan, Bing, et al.
Publicado: (2022)

Prevalence of HPV 16 and HPV 18 Lineages in Galicia, Spain
por: Pérez, Sonia, et al.
Publicado: (2014)

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
por: Szarewski, Anne, et al.
Publicado: (2013)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58
por: de Sanjosé, Silvia, et al.
Publicado: (2019)

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors
por: Damm, Oliver, et al.
Publicado: (2009)

Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali
por: Téguété, Ibrahima, et al.
Publicado: (2017)

Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18
por: Bogaards, Johannes A, et al.
Publicado: (2019)

Is It Time to Genotype Beyond HPV16 and HPV18 for Cervical Cancer Screening?
por: Chua, Brandon Wen Bing, et al.
Publicado: (2022)

HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation
por: Yu, Lulu, et al.
Publicado: (2022)

Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females—Results from a community‐randomized trial
por: Lehtinen, Matti, et al.
Publicado: (2019)

Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection
por: Gradissimo, Ana, et al.
Publicado: (2021)

Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence
por: Arbyn, Marc, et al.
Publicado: (2020)

HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial
por: Tsang, Sabrina H., et al.
Publicado: (2022)

Cervarix(™): a vaccine for the prevention of HPV 16, 18-associated cervical cancer
por: Monie, Archana, et al.
Publicado: (2008)

In silico design of a multi-epitope vaccine against HPV16/18
por: Sanami, Samira, et al.
Publicado: (2022)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

HPV-16, HPV-58, and HPV-33 are the most carcinogenic HPV genotypes in Southwestern China and their viral loads are associated with severity of premalignant lesions in the cervix
por: Long, Wenbo, et al.
Publicado: (2018)

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
por: Mariz, Filipe Colaço, et al.
Publicado: (2020)

Absence of HPV 16 and 18 DNA in breast cancer.
por: Wrede, D., et al.
Publicado: (1992)

Monitoring HPV16/18 immunisation in England and elsewhere
por: Franceschi, S
Publicado: (2010)

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types
por: Kavanagh, K, et al.
Publicado: (2014)

Rapid detection of high-risk HPV16 and HPV18 based on microchip electrophoresis
por: Fan, Zhaoxuan, et al.
Publicado: (2020)

Assessment of HPV 16, HPV 18, p16 expression in advanced stage laryngeal cancer patients and prognostic significance()()
por: Dogantemur, Selman, et al.
Publicado: (2019)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
por: Schwarz, Tino F., et al.
Publicado: (2017)

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
por: Folschweiller, Nicolas, et al.
Publicado: (2020)

Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2019)

Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
por: Hu, Shangying, et al.
Publicado: (2020)

Strong reduction in prevalence of HPV16/18 and closely related HPV types in sexually active adolescent women following the introduction of HPV vaccination in Argentina
por: González, Joaquín Víctor, et al.
Publicado: (2020)

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India
por: Diaz, M, et al.
Publicado: (2008)

Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign
por: Vu, Lan TH, et al.
Publicado: (2013)

Dynamic response of HPV16/anti-HPV16 pairs with unbinding events studied by atomic force microscopy
por: Lin, Shiming, et al.
Publicado: (2016)

Clinical Significance of an HPV DNA Chip Test with Emphasis on HPV-16 and/or HPV-18 Detection in Korean Gynecological Patients
por: Yeo, Min-Kyung, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0lbt5j3eucplbum6g7kkkadiim